AZD-1480

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameAZD-1480
Drug Alias NameAZD-1480
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitorsTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK2Tyrosine-protein kinase JAK1
Therapy Area/IndicationsSolid tumoursPrimary MyelofibrosisNeoplasm Metastasis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFranceSouth Korea
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsSolid tumoursPrimary MyelofibrosisNeoplasm Metastasis +[5] 

Other Information

ATC CodeN/A
Related LinksN/A